410 Medical Secures $12 Million. Propels LifeFlow Critical Care Expansion. Next-Gen Device Planned for 2027.
July 18, 2026, 9:38 am
Location: United States, North Carolina, Durham
Employees: 11-50
Founded date: 2000
410 Medical secured $12 million in funding. The investment fuels LifeFlow's commercial expansion. It also advances a next-generation critical care device. Orlando Health Ventures led the oversubscribed round. This capital accelerates rapid fluid delivery technology. LifeFlow aids patients with sepsis and shock. The firm plans a 2027 launch for its new product. This move strengthens critical care innovations nationwide.
410 Medical, a North Carolina firm, is an innovator. It focuses on advanced resuscitation technologies. The company just closed a significant financing round. An oversubscribed $12 million fuels this investment. The capital will drive commercial growth. It will also fund a next-generation device.
Orlando Health Ventures led the funding. Many prominent investors joined. Hatteras Venture Partners participated. Ballad Health contributed. OSF Healthcare backed the initiative. Rex Health Ventures also invested. CU Healthcare Innovations Fund joined. Sarnova added its support. Catalyst by Wellstar provided funding. Tampa General became an investor. A new strategic partner remains undisclosed. This investor group is crucial. Many participants are hospital-based. They represent major health systems. This reflects direct clinical validation. These investors understand LifeFlow's impact. Their investment shows profound confidence.
410 Medical launched in 2013. Its mission remains clear. Improve care for critically ill patients. The company’s flagship product is LifeFlow. FDA clearance came in 2016. LifeFlow revolutionized fluid administration. It swiftly delivers fluid and blood products. This is vital for patients facing critical conditions. Sepsis is one such threat. Hemorrhagic shock is another. Other life-threatening states benefit. Speed is paramount in these scenarios. Every minute counts for patient survival. Delays can be fatal. LifeFlow mitigates these risks.
LifeFlow is a proven solution. It is currently deployed across the nation. Over 500 hospitals utilize the technology. EMS agencies also depend on it. Healthcare providers trust LifeFlow. Nearly 80,000 patients have received treatment. This demonstrates significant adoption. It shows widespread clinical impact. The device enables rapid, effective resuscitation. It reduces critical treatment delays. Improved patient outcomes are the ultimate goal. LifeFlow directly contributes to this success.
The new funding targets expansion. 410 Medical will accelerate adoption. More hospital systems will implement LifeFlow. Additional EMS agencies will integrate it. The company aims for broader market penetration. This extends LifeFlow’s reach. More patients will gain access to this vital tool. It strengthens the entire critical care ecosystem. Increased availability saves more lives.
Investment also fuels innovation. A next-generation LifeFlow infuser is planned. This new device builds on extensive experience. Nearly ten years of field data informed its design. Front-line clinician feedback shaped its development. The goal is to address unmet needs. Speed enhancements are a priority. Portability improvements are critical. Ease of use will be central. These features matter in demanding environments. Resuscitative care demands precision and efficiency. The new platform will launch in 2027. It promises advanced capabilities. Enhanced features will benefit clinicians. It will further streamline rapid fluid delivery. This next-gen device underscores 410 Medical’s commitment. The company continually strives for better solutions. It focuses on evolving critical care demands. This investment ensures future growth. It secures ongoing technological advancement.
410 Medical stands at the forefront. It delivers life-saving medical devices. The company addresses urgent patient needs. Its focus remains on emergency situations. Every second matters during crisis. LifeFlow provides essential support. It ensures timely interventions. This directly impacts patient survival rates. Its technology saves lives.
The medical device sector thrives on innovation. 410 Medical exemplifies this drive. Its success draws significant investor interest. Health systems are investing directly. This trend validates critical medtech solutions. These solutions offer clear clinical benefits. They also show economic value. Hospitals see tangible results. They observe improved patient management. This fuels further investment in the sector. It reinforces the value of specialized medical technology.
The investment round was oversubscribed. This signals strong market confidence. Investors believe in 410 Medical’s mission. They trust its product roadmap. The company has demonstrated commercial viability. Its technology has proven effective. This financial backing validates its trajectory. It reinforces its position in critical care. It secures a leading role for the company.
The impact extends beyond the company. It influences broader healthcare strategies. Rapid resuscitation is a cornerstone of emergency medicine. Technologies like LifeFlow improve standard protocols. They empower healthcare professionals. They deliver advanced care at the point of need. This accelerates positive outcomes. It mitigates severe health consequences. This improves public health.
410 Medical’s leadership is strategic. Its commitment to research continues. Development of next-gen solutions remains a priority. This ensures a pipeline of innovation. The company aims to stay ahead. It anticipates future challenges in critical care. Its vision involves continuous improvement. This benefits countless patients globally. It drives medical progress.
This funding round marks a new chapter. 410 Medical is poised for significant growth. Its LifeFlow technology will reach more clinicians. Its next-gen device will set new standards. The company advances emergency medicine. It strengthens critical care capabilities nationwide. Patients facing life-threatening conditions stand to benefit most. The future of rapid resuscitation looks brighter.
410 Medical, a North Carolina firm, is an innovator. It focuses on advanced resuscitation technologies. The company just closed a significant financing round. An oversubscribed $12 million fuels this investment. The capital will drive commercial growth. It will also fund a next-generation device.
Orlando Health Ventures led the funding. Many prominent investors joined. Hatteras Venture Partners participated. Ballad Health contributed. OSF Healthcare backed the initiative. Rex Health Ventures also invested. CU Healthcare Innovations Fund joined. Sarnova added its support. Catalyst by Wellstar provided funding. Tampa General became an investor. A new strategic partner remains undisclosed. This investor group is crucial. Many participants are hospital-based. They represent major health systems. This reflects direct clinical validation. These investors understand LifeFlow's impact. Their investment shows profound confidence.
410 Medical launched in 2013. Its mission remains clear. Improve care for critically ill patients. The company’s flagship product is LifeFlow. FDA clearance came in 2016. LifeFlow revolutionized fluid administration. It swiftly delivers fluid and blood products. This is vital for patients facing critical conditions. Sepsis is one such threat. Hemorrhagic shock is another. Other life-threatening states benefit. Speed is paramount in these scenarios. Every minute counts for patient survival. Delays can be fatal. LifeFlow mitigates these risks.
LifeFlow is a proven solution. It is currently deployed across the nation. Over 500 hospitals utilize the technology. EMS agencies also depend on it. Healthcare providers trust LifeFlow. Nearly 80,000 patients have received treatment. This demonstrates significant adoption. It shows widespread clinical impact. The device enables rapid, effective resuscitation. It reduces critical treatment delays. Improved patient outcomes are the ultimate goal. LifeFlow directly contributes to this success.
The new funding targets expansion. 410 Medical will accelerate adoption. More hospital systems will implement LifeFlow. Additional EMS agencies will integrate it. The company aims for broader market penetration. This extends LifeFlow’s reach. More patients will gain access to this vital tool. It strengthens the entire critical care ecosystem. Increased availability saves more lives.
Investment also fuels innovation. A next-generation LifeFlow infuser is planned. This new device builds on extensive experience. Nearly ten years of field data informed its design. Front-line clinician feedback shaped its development. The goal is to address unmet needs. Speed enhancements are a priority. Portability improvements are critical. Ease of use will be central. These features matter in demanding environments. Resuscitative care demands precision and efficiency. The new platform will launch in 2027. It promises advanced capabilities. Enhanced features will benefit clinicians. It will further streamline rapid fluid delivery. This next-gen device underscores 410 Medical’s commitment. The company continually strives for better solutions. It focuses on evolving critical care demands. This investment ensures future growth. It secures ongoing technological advancement.
410 Medical stands at the forefront. It delivers life-saving medical devices. The company addresses urgent patient needs. Its focus remains on emergency situations. Every second matters during crisis. LifeFlow provides essential support. It ensures timely interventions. This directly impacts patient survival rates. Its technology saves lives.
The medical device sector thrives on innovation. 410 Medical exemplifies this drive. Its success draws significant investor interest. Health systems are investing directly. This trend validates critical medtech solutions. These solutions offer clear clinical benefits. They also show economic value. Hospitals see tangible results. They observe improved patient management. This fuels further investment in the sector. It reinforces the value of specialized medical technology.
The investment round was oversubscribed. This signals strong market confidence. Investors believe in 410 Medical’s mission. They trust its product roadmap. The company has demonstrated commercial viability. Its technology has proven effective. This financial backing validates its trajectory. It reinforces its position in critical care. It secures a leading role for the company.
The impact extends beyond the company. It influences broader healthcare strategies. Rapid resuscitation is a cornerstone of emergency medicine. Technologies like LifeFlow improve standard protocols. They empower healthcare professionals. They deliver advanced care at the point of need. This accelerates positive outcomes. It mitigates severe health consequences. This improves public health.
410 Medical’s leadership is strategic. Its commitment to research continues. Development of next-gen solutions remains a priority. This ensures a pipeline of innovation. The company aims to stay ahead. It anticipates future challenges in critical care. Its vision involves continuous improvement. This benefits countless patients globally. It drives medical progress.
This funding round marks a new chapter. 410 Medical is poised for significant growth. Its LifeFlow technology will reach more clinicians. Its next-gen device will set new standards. The company advances emergency medicine. It strengthens critical care capabilities nationwide. Patients facing life-threatening conditions stand to benefit most. The future of rapid resuscitation looks brighter.